

Japan Pharma Outlook 2015: 2015 –Year to Watch Out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives

<https://marketpublishers.com/r/J6083E15C07EN.html>

Date: January 2015

Pages: 153

Price: US\$ 2,000.00 (Single User License)

ID: J6083E15C07EN

Abstracts

The new pricing system adopted in Japan from April -2014 (Annexure 1) is a game changer initiative. It pains most of the companies - whether generic or innovator. The most of the companies are revalidating their domestic (and thus overseas) strategies to adopt with new regulations. For the innovators – testing Authorized Generics (AGs) phenomenon for protecting their long-listed sales against generic could be one of new choice in Japan. The format and regulations for AG's are still not clear in Japan, however with the largest Japanese product Blopress AG's launched recently and generic companies in queue to compete with their generic versions will make the things lucid for the fate of AG's in Japan.

For most of the generic companies focusing on reducing manufacturing costs, and for many of them to venture in biosimilars space as a new growth avenue would be focus. The trends suggest that Japanese companies may need to set up or alliance with companies overseas for manufacturing. In this note of Outlook-15, we look deeper into these trends to anticipate likely near term changes of Japanese pharma industry.

In innovation space, after Oncology, regenerative medicine and Orphan disease are the areas where Japanese innovator companies are focusing its R & D efforts. While from late stage pipeline/new launch, Edoxaban, Lenvatinib, Entyvio, Brintellix, and Ixazomib are the few important NCEs, uptake of which will decide Japanese Innovator growth in Global market. In this report- We analyzed pipeline, strategies and key growth drivers of 13 major Japanese biopharma companies (Pure play innovators/ Innovators+ Generics/Pure play generics) and detailed our view on these growth drivers along with their interest for inlicensing external innovation from the globe for increasing R&D productivity.

Contents

COMPANY ANALYSIS:

ASTELLAS - XTANDI UPTAKE IN PRE-CHEMO PC, ISAVUCONAZOLE US APPROVAL & UPTAKE WILL PROVIDE CUSHION TO NEXT BATCH OF INNOVATION (ROXADUSTAT, CMV VACCINE, ASP8273)!

Xtandi- Xtandi's early stage clinical data in HER2 positive, HR+ve, AR +ve Breast cancer and Data from TERRAIN/STRIVE study in early PC will drive Xtandi momentum in 2015, while PhIII data read out of ARN-509 from SPARTAN study is the key near term threat

Isavuconazole: Our view on US approval and Uptake

Myrbetriq: Myrbetriq uptake in OAB market – a blockbuster potential likely- EB178 (FDC/- combo of Solifenacin+ Mirabegron) combination - Next Batch of Innovation

Roxadustat- Can change the current treatment paradigm mainly in CKD-NDPatients- AKB-6548 is the key competitor

Key advantage over current EPO

Biosimilar EPO is not a threat

Pipeline HIF inhibitors and clinical data comparison

ASP-8273 (Ph 1, Irreversible mutant selective EGFR inhibitor)

Evolocumab

Table 1: Deals done by Astellas in 2013, 2014

Table 2: Pipeline Early stage Androgen Receptor antagonist

Table 3: Competitive landscape for Antifungals

Table 4: Competitive landscapes for OAB drugs

Table 5: Pipeline HIF alpha stabilizer- AKEBIA AKB-6548 is closest competitor

Table 6: Competitive landscape- Anti PCSK9 MAB- ALIROCUMAB vs.

EVOLOCUMAB

Chart: 1, 2 – Current and Future use of anti androgens in treatment of Prostate CancerChugai -

ALECTINIB, ACE910 GLOBAL SUCCESS – NEXT GROWTH DRIVER! CHUGAI'S - BREAST CANCER FRANCHISEE: BREAST CANCER FRANCHISEO PERJETA WILL BE THE KEY GROWTH DRIVER FOR THE FRANCHISEE-NOT KADCYLA –

In long term, Perjeta + Herceptin + Chemo will be the standard of care vs. currently Herceptin + chemo. Kadcyla will cater 2nd line market, while data from APHINITY trial in 2016 will decide Perjeta + Herceptin use for adjuvant setting in Breast cancer

Failure of MARIANNE Study further increases threat of Herceptin biosimilar
Chugai's NSCLC franchisee:

MPDL3280A (anti-PDL1 mAB, PhIII, NSCLC, Melanoma) - It is in PhIII in Japan and for NSCLC indication- Nivolumab is the closest competitor.

April 2014 price cut to Long listed products resulted in sales decline of Suvenyl, Sigmart and Alfarol

MPDL3280A – Anti PD1 from Roche- competitive landscape and status in Japan

Table 1: Deals Done By Chugai Pharma in 2013-2014

Table 2: Ongoing Important Clinical Studies of Kadcyra in Late Stage Her 2 Positive Cancers

Table 3: ACTEMRA - ONGOING GLOBAL TRIALS

DAIICHI SANKYO -EDOXABAN UPTAKE + RANBAXY/SUN CLOSURE WILL PROVIDE MOMENTUM IN 2015!

Ranbaxy +Sun= Sun = 9% equity stake in New Sun- Exit or hold???

Vision 2017 Revision is expected around FY03/15 results:

Edoxaban: A blockbuster potential likely despite restricted US launch and will be 4th Entrant in NOAC market

Acquisition of Ambit bioscience

Quizaritinib

Other Assets from Ambit

Other Assets in Pipeline- CL 108 and Etanercept biosimilar

JP domestic market – Long listed products sales decline

Daiichi Sankyo Espha (DSE) – New pricing policy make difficult road ahead

Table 1: Edoxaban – Possible Scenario Analysis and Peak Sales Estimate

Table 2: % Patients Crcl

I would like to order

Product name: Japan Pharma Outlook 2015: 2015 –Year to Watch Out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives

Product link: <https://marketpublishers.com/r/J6083E15C07EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/J6083E15C07EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

